Clinical Trial Update: Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching virologically suppressed HIV-1 patients from dolutegravir-containing regimens to bictegravir/emtricitabine/tenofovir alafenam…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ABC/3TC (abacavir/lamivudine)
• ABC/DTG/3TC (abacavir/dolutegravir/lamivudine)
• B/F/TAF (emtricitabine/tenofovir alafenamide/cobicistat-darunavir)
• Dolutegravir (dolutegravir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-07-23